Consensus. Chinese Consensus on Combination Therapy of Chronic Hepatitis B

[1]  Z. Lang,et al.  A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol , 2011, Hepatology International.

[2]  T. Shi,et al.  [Treatment with interferon and thymosin alpha-1 versus interferon monotherapy for HBeAg positive chronic hepatitis B: a meta-analysis]. , 2011, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[3]  M. Wan.  [The present situation and pondering on antiviral therapy in patients with decompensated cirrhosis]. , 2010, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[4]  V. Wong,et al.  Durability of peginterferon alfa‐2b treatment at 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B , 2010, Hepatology.

[5]  Hong Tang,et al.  Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis , 2009, Virology Journal.

[6]  M. Sherman,et al.  Strategies for managing coinfection with hepatitis B virus and HIV , 2009, Cleveland Clinic Journal of Medicine.

[7]  P. Marcellin,et al.  Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B , 2009, Hepatology.

[8]  T. Asselah,et al.  Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients , 2009, Hepatology.

[9]  Y. Liaw,et al.  On-Treatment Outcome Prediction and Adjustment during Chronic Hepatitis B Therapy: Now and Future , 2009, Antiviral therapy.

[10]  A. Gramenzi,et al.  In vitro effect of thymosin‐alpha1 and interferon‐alpha on Th1 and Th2 cytokine synthesis in patients with eAg‐negative chronic hepatitis B , 2008, Journal of viral hepatitis.

[11]  替比夫定中国路线图专家讨论组.  [Chinese roadmap for treating chronic hepatitis B with telbivudine]. , 2008, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[12]  H. Tillmann,et al.  Telbivudine versus lamivudine in patients with chronic hepatitis B. , 2008, The New England journal of medicine.

[13]  P. Marcellin,et al.  HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa‐2a for HBeAg‐positive chronic hepatitis B , 2008, Hepatology.

[14]  F. Zoulim,et al.  Hepatitis B: reflections on the current approach to antiviral therapy. , 2008, Journal of hepatology.

[15]  P. Lampertico,et al.  Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. , 2007, Gastroenterology.

[16]  N. Nikolaidis,et al.  Lamivudine/pegylated interferon alfa‐2b sequential combination therapy compared with lamivudine monotherapy in HBeAg‐negative chronic hepatitis B , 2007, Journal of gastroenterology and hepatology.

[17]  E. Keeffe,et al.  Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  Liu Jian-pin.  Glycyrrhizin and derivatives for treatment of chronic hepatitis B:A systematic review of randomized controlled trials , 2007 .

[19]  J. Stockman,et al.  Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B , 2007 .

[20]  P. Schirmacher,et al.  Peginterferon alpha‐2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B , 2006, Hepatology.

[21]  N. Leung,et al.  A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. , 2005, Gastroenterology.

[22]  V. Wong,et al.  A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-2b and Lamivudine with Lamivudine Alone , 2005, Annals of Internal Medicine.

[23]  D. Machin,et al.  A Randomized, Placebo-Controlled Trial of Thymosin-α1 and Lymphoblastoid Interferon for Hbeag-Positive Chronic Hepatitis B , 2005, Antiviral Therapy.

[24]  Song Yan-yan.  Meta-analysis of document on diammonium Glycyrrhizinate in treatment of patients with chronic hepatitis B , 2005 .

[25]  Lei Wang,et al.  [Occurrence and predictive factors of hepatitis B virus polymerase YMDD variation among patients with chronic hepatitis B and liver cirrhosis during lamivudine therapy]. , 2004, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[26]  J. M. Harris,et al.  Pegylation: a novel process for modifying pharmacokinetics. , 2001, Clinical pharmacokinetics.

[27]  D. Häussinger,et al.  Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. , 1996, The New England journal of medicine.

[28]  A. Detsky,et al.  Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1993, Annals of Internal Medicine.